6 days Ago By ABMN Staff
Royal Bank of Canada reissued their outperform rating on shares of Beigene ( NASDAQ:ONC – Free Report ) in a research note released on Monday morning, Benzinga reports. They currently have a $312.00 price objective on the stock.
Several other analysts have also recently commented on ONC. Macquarie boosted their price target on shares of Beigene from $259.00 to $313.
00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. TD Securities reiterated a “buy” rating and issued a $334.00 price target on shares of Beigene in a research note on Thursday, April 24th.
JMP Securities set a $348.00 price target on shares of Beigene in a research note on Friday, February 28th. Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and upped their target price for the company from $207.
00 to $320.00 in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co.
upped their target price on shares of Beigene from $311.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, April 21st.
Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $318.88. Read Our Latest Stock Analysis on ONC Beigene Stock Performance Beigene ( NASDAQ:ONC – Get Free Report ) last announced its quarterly earnings results on Thursday, February 27th.
The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.
55). The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.
09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.
94%. On average, equities research analysts predict that Beigene will post -5.82 earnings per share for the current year.
Insider Activity In related news, COO Xiaobin Wu sold 30,654 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.
96. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink . Also, Director Bros.
Advisors Lp Baker sold 732,827 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.
00. Following the transaction, the director now owns 730,642 shares in the company, valued at $189,966,920. The trade was a 50.
07 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last three months, insiders have sold 1,146,048 shares of company stock worth $295,198,300.
6.62% of the stock is currently owned by corporate insiders. About Beigene ( Get Free Report ) BeiGene Ltd.
Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V.
Oyler on October 28, 2010 and is headquartered in George Town, KY. Featured Stories Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter .
.
